Turning Point’s Repotrectinib Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of ROS1-Positive Metastatic Non-Small Cell Lung Cancer

 Turning Point’s Repotrectinib Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of ROS1-Positive Metastatic Non-Small Cell Lung Cancer

Turning Point’s Repotrectinib Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of ROS1-Positive Metastatic Non-Small Cell Lung Cancer

Shots:

  • The US FDA has been granted BTD for the treatment of patients with ROS1+ metastatic NSCLC who have not been treated with ROS1 TKI-naïve
  • The designation is based on P-I & P-II portion of TRIDENT-1 study of repotrectinib in TKI-naïve ROS1-positive NSCLC patients. The study is currently evaluating patients in multiple potentially registrational cohorts
  • The company plans to report updated P-II TRIDENT-1 study results in patients with TKI-naive ROS1-positive NSCLC at the World Conference on Lung Cancer on Jan 31, 2021

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Biocom

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post